The AIM-listed skin health company said in a statement that the application covered the use of its SkinBiotix technology for increasing filaggrin levels in the skin.
Filaggrin is a protein that is vital for cells to mature properly into the tough outer layer of the skin, with deficiencies leading to dryness and irritation as well as the potential development of conditions such as eczema.
The company said research in its labs had shown that SkinBiotix could significantly increase the amount of filaggrin in human skin models.
This is the second successful test of the group's technology, following earlier proof that SkinBiotix increases the 'tight junction' which exists in the inner layer of skin.
The company added that the observation that the technology can improve both the surface and inner layers of skin suggests that SkinBiotix would be therapeutically useful in a range of conditions, such as eczema.
SkinBioTherapeutics has already finalised plans for a human study around the cosmetic application of its SkinBiotix technology, which is expected to be carried out in the third quarter of this year.
SkinBiotix continuing to prove its uniqueness
Dr Cath O’Neill, chief executive of SkinBioTherapeutics, said: "SkinBiotix is continuing to prove its uniqueness as a platform via scientific testing. Following the successful work in skin models on filaggrin production, we are looking to increase the value and scope of our intellectual property with the filing of this patent.
"This is a continuation of our strategy to create an IP portfolio that allows us to robustly protect what we believe is a technology of significant commercial value in key global dermatalogical markets."
In a note to clients, analysts at 'house' broker Northland Capital commented: “These findings regarding filaggrin production combined with previous observations on tight junctions indicate that the SkinBiotix platform has beneficial properties on both the surface and inner layers of skin and could be therapeutically useful in a range of skin conditions, including eczema.”
They added: “The filing of this patent shows the Company is continuing to protect its IP portfolio surrounding its SkinBiotix technology.
“The Company’s first patent (covering the use of bacteria and lysates in the treatment of skin in health and disease) has been granted in Australia, New Zealand and Russia with active prosecution progressing in Europe, USA and China.”
In early afternoon trading, SkinBioTherapeutics shares were up 6.3% at 17p.
-- Adds analyst comment; updates share price --